552c7ae14ClaimYounger patients should receive priority when lifesaving treatment is scarceAgreeDisagree2
552c7ae14ClaimParents should be allowed to select embryos against adult-onset inherited diseaseAgreeDisagree
552c7ae14ClaimMedicare coverage of anti-obesity drugs would add about $35 billion to federal spending from 2026 to 2034AgreeDisagree
552c7ae14ClaimSemaglutide carries a regulator-confirmed risk of NAION, a very rare optic nerve conditionAgreeDisagree
552c7ae14ClaimSemaglutide and tirzepatide are cost-effective for obesity at current net pricesAgreeDisagree
552c7ae14ClaimMost adults with obesity but without diabetes stop GLP-1 drugs within a yearAgreeDisagree
552c7ae14ClaimMedicare coverage of weight-loss drugs could save Medicare $175–245 billion over ten yearsAgreeDisagree
552c7ae14ClaimParents should not be allowed to select embryos for predicted intelligenceAgreeDisagree30
552c7ae14ClaimPlacebo-controlled trials should be required before approving new medicinesAgreeDisagree
552c7ae14ClaimNew medicines should have to outperform existing treatments before approvalAgreeDisagree
552c7ae14ClaimGovernments should license publicly funded drug patents to competitors when prices are unaffordableAgreeDisagree
552c7ae14ClaimMedical research grants should be allocated by lottery among proposals that meet a quality thresholdAgreeDisagree
552c7ae14ClaimPublicly funded medical research should be freely available immediately upon publicationAgreeDisagree
552c7ae14ClaimDrugs for serious illnesses should qualify for accelerated approval based on biomarkers before patient benefit is provenAgreeDisagree
552c7ae14ClaimTerminally ill patients should be allowed experimental drugs before trials establish effectivenessAgreeDisagree
552c7ae14ClaimPublic health systems should prioritize total health gains over treating the sickest firstAgreeDisagree